At the recent OBN C-Suite Breakfast Discussion on ‘Enhancing TTO and Spin-out Partnerships to Support Growth in Life Sciences,’ industry leaders, investors, tech transfer advocates, entrepreneurs, and academics (me!) came together to share insights from the front lines. This event aimed to dissect the challenges and opportunities in licensing and commercialisation, fostering a transparent dialogue between the investor community, industry, and Technology Transfer Offices (TTOs).

The conversation spotlighted critical issues such as the equity stakes universities take in new ventures, which can often become a stumbling block for future investment, and the nuanced roles of foreground and background IP. Our goal was to better support emerging entrepreneurs by identifying what more is needed to help commercialise and scale the often untapped innovation and ambition within our institutions.

The morning kicked off with keynote presentations from Dr. Lisa Smith, CEO of Midlands Mindforge, an investment company co-founded by eight research-intensive universities, and Dr. Michael Joseph, Business Development Manager at Brunel University London, who oversees R&D and innovation partnerships in Healthcare and Medical Technology. Their insights set the stage for a dynamic round-table discussion, where senior leaders from the life sciences sector delved into the practicalities and potential of enhancing these critical partnerships.

As we dissect the highlights from this discussion, it’s clear that while the challenges are formidable, the opportunities for growth and innovation are boundless. Join me as I explore my personal notes and key takeaways from this pivotal event.

Key lessons you can't miss:

• Foster collaboration: Leverage diverse expertise to drive innovation.

• Engage early career scientists: Infuse fresh ideas by involving new researchers.

• Build strategic partnerships: Open resources and opportunities through key alliances.

• Promote internal networking: Strengthen community ties within your organisation.

• Address real-world challenges: Focus on solving practical, topical issues.

• Support professional development: Guide members in securing fellowships and grants.

• Stay cutting-edge: Organise events on the latest scientific advancements.

• Champion diversity and inclusion: Ensure varied perspectives are valued.

• Utilise existing networks: Enhance impact through established connections.

• Highlight success stories: Inspire with member achievements and initiatives.

• Funders must prioritize and reward: innovative, high-risk, high-impact projects.

Personal Notes from the Breakfast

Entrepreneurial Ecosystem and Alumni Involvement

Michael emphasised that a robust entrepreneurial ecosystem within the university fosters a culture of giving back. Graduates who create jobs often employ Brunel students, reinforcing this cycle of support. This ethos is notably strong in the US, where school pride and active alumni committees play a significant role.

Academia-SME Collaborations

Michael also highlighted the importance of strong collaborations between academia and small and medium-sized enterprises (SMEs). He mentioned Brunel's RIEm2025 initiative, which offers small grants to support innovative ideas backed by both academics and industry scientists.

Funding Challenges and Market Failures

Lisa discussed how her company was formed in response to the lack of accessible funding in the Midlands. She distinguished her investment company from traditional funds, noting that the shorter investment lifecycle of funds forces biotech companies to sell their intellectual property or exit prematurely. This, she argued, represents a fundamental market failure.

Key Factors for a Thriving Entrepreneurial Ecosystem

Lisa identified three critical factors for a thriving entrepreneurial ecosystem:

1. Capacity to Scale

2. Size of Fund

3. Size of Cheque

She stressed that to retain companies in the UK, funds need to be large enough to support companies through to IP maturity, allowing for the issuance of substantial financial support when needed.

Discussion Highlights and Key Points

The Q&A session brought up several important issues that need addressing to strengthen the ecosystem:

1. USIT Guide and standardisation

   • The USIT guide helps entrepreneurs with negotiations, but its usage is uncertain.

   • Lisa noted that in equity splits, the founders' share is more crucial than the university's share.

   • There is a debate on the need for standardisation of documents. While standardisation can save resources and ensure fair treatment, it may contradict the entrepreneurial model of survival of the fittest.

2. Intellectual property (IP) protection

   • Enhancing our ability to protect IP and ring-fence it within specific verticals or regions is crucial.

3. Cultural shifts

   • Promoting more ambitious undertakings by young entrepreneurs.

   • Normalising the concept of the "5x entrepreneur" and accepting failure as part of the process.

   • Encouraging entrepreneurship before students even reach university.

   • Shifting the perception of the one-time successful entrepreneur turning into a tech transfer officer or passive investor.

4. Staffing new companies

   • Addressing the pull into the spinout model.

   • There’s increased immigrant uptake in entrepreneurial training and job opportunities, leading to a lack of locally trained talent.

   • Scientists are often encouraged to travel abroad for better learning opportunities, leading to a lack of locally trained talent.

   • SMEs are often restricted to hire local talent with right-to-work permits but are restricted by local talent pools.

   • Solutions might include:

     • Allowing SMEs to hire immigrants on shorter-term contracts.

     • Investing in local talent by reserving some entrepreneurial opportunities for them.

     • Incentivising the return of highly trained and skilled individuals to the UK workforce.

These points underscore the need for strategic initiatives & cultural changes to foster a more robust and inclusive entrepreneurial ecosystem in the UK.

Lack of ambition in the UK innovation ecosystem?

During the discussion, a question was posed to attendees about whether the UK ecosystem lacks ambitious young scientists. Having worked in both the US and the UK as a scientist, I can provide the following perspective:

Early career scientists in the UK are just as hungry and ambitious as their US counterparts, but the infrastructure and ethos are entirely different.

The main difference between the US and UK entrepreneurial ecosystems lies in the approach to risk-taking and the support structures for innovation. In the US, there is a strong culture of embracing high-risk, high-reward projects, and failure is often seen as a valuable learning experience. This attitude is supported by a robust network of venture capital, angel investors, and an entrepreneurial community that encourages bold ventures and rapid scaling. In the US, if you’re trying something new as an entrepreneur you are a rock star.

In contrast, the UK ecosystem tends to be more risk-averse. Funding structures and institutional support often favour more conservative, incremental advancements. This cautious approach can stifle the ambition of young scientists and entrepreneurs, as there is less encouragement and fewer resources available for pursuing innovative and high-risk projects. Additionally, the availability of large-scale funding is limited, as discussed by Lisa, making it challenging for startups to secure the necessary capital to scale effectively. In the UK, if you’re trying something new as an entrepreneur you are probably crazy.

But the problem, from a biotech perspective, might also start from academia. The academic mindset among many established group leaders often focuses on fundamental research, with much less emphasis on translating discoveries into commercial ventures. One might ask: do academics lack the right incentives to promote translational projects in their labs, given that their performance is still primarily assessed based on publications and the criteria set by their grant funders? This traditional approach could be limiting the drive for entrepreneurial activities among younger scientists, who may feel discouraged from pursuing translational research and innovation to meet the publication or grant requirements.

While both systems have their strengths, the UK's more conservative approach may hinder the full potential of its entrepreneurial talent. To foster a more vibrant and dynamic innovation landscape, a cultural shift is needed—one that encourages greater ambition, risk-taking, and support for translational research. This shift might start with the funders, who also need to evolve to prioritize and reward innovative and high-impact projects. Only by addressing these systemic issues can the UK fully unleash the potential of its entrepreneurial ecosystem.

Disclaimers:
* My personal notes should be largely correct, though I'm only human!

One day I’ll get you to … Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

Permalink

]]>Eggs-on-Toast with Tech Transfer TitansLola AnaidSun, 07 Jul 2024 23:02:15 +0000https://www.anaidbenitez.com/entrepreneurs-notebook/biotrinity20246526e84a08859a53d0aeb713:65afdcdbd951e626b5430ec6:6687ecc44de3695244fab3c2

BioTrinity 2024, organised by OBN, offered a rich tapestry of knowledge, innovation, and strategic insights through its business track sessions. This post dissects each presentation, drawing out the key facts and lessons learned from each session.

Key Lessons You Can't Miss

Your business model will only succeed, if and only if, you’re:

• harnessing advanced technologies like AI,

• playing your part to contribute to a robust entrepreneurial ecosystem,

• incorporating innovative strategies like personalised medicine,

• strategically planning for taxes, and

• staying abreast of regulatory changes.

These and many other factors explored below are critical to thriving in the competitive landscape of the biotech industry.

Inside Look: My BioTrinity Experience

BioTrinity felt like a science conference on steroids. The schedule was jam-packed with company presentations focused on their science. All presenters had to defend the practical real-world reasons behind their research and the viability of their business proposition - lessons some academics often miss. There was a huge emphasis on partnering, which is a stark contrast to academic conferences where networking might happen through poster sessions. At BioTrinity, focused partnering meetings ran from 8am to closing time in 20-minute slots, in a giant room with over 50 tables. These meetings were incredibly useful, not just for partnering, but for private introductions, company discovery, fundraising, and even addressing simple questions.

Something surprising to me was the number of Contract Research Organisations (CROs) present, reaching out to academics like me to facilitate our research. As scientists, we're often sheltered from these services, with the emphasis being on doing it all on our own. Academia is slowly progressing on this front, but we have a long way to go. I saw a lot of engagement from companies wanting to establish better relationships and partnerships with academic labs and institutes. The University of Oxford did this well by presenting a poster as a touchpoint for companies to reach out. Others, like the Crick Institute, took full advantage of the partnering system.

Tim Davis’s presentation on the benefits of London as a listing venue was one of the most intriguing and informative sessions (see the detailed spotlight on Davis's session further below). He highlighted the resilience and opportunities within the UK's financial markets, despite global economic challenges. Davis provided insights into the UK's substantial pool of capital, regulatory reforms aimed at making public markets more accessible, and the advantages of listing in London compared to NASDAQ. His discussion on the supportive ecosystem for growth companies and the comprehensive investor environment offered practical lessons on leveraging London's strengths for business growth.

My favourite talk happens to be the one I could relate to the most. Tony Hickson, Chief Business Officer for Cancer Research UK and Cancer Research Horizons, shared his thoughts on bridging academia with entrepreneurship, offering the perspective that these two paths don’t need to be mutually exclusive. He led the conversation towards creating a more collaborative environment that allows early career researchers to explore the translational and commercial potential of their research.

Big Pharma Showcase

MARK DOWLING•SUE BAILEY•ANDREW MCCONAGHIE•REBECCA CANTER•CHLOÉ LEPRÉTRÉ

Summary: The Big Pharma Showcase highlighted the strategic approaches and innovations by major pharmaceutical companies. It emphasised the integration of advanced technologies and collaborative efforts to streamline drug development.

Key Facts:

• Major pharmaceutical companies are increasingly leveraging AI and machine learning to accelerate drug discovery.

• Partnerships with biotech startups and academic institutions are crucial for accessing novel technologies.

• Personalised medicine is a significant focus, aiming to provide tailored treatments based on genetic profiles.

Lessons Learned:

• Embracing technology and collaboration is essential for maintaining competitiveness in the pharmaceutical industry.

• Innovative strategies such as personalised medicine can offer significant therapeutic benefits and market advantages.

• Large pharmaceutical companies must balance short-term profitability with long-term R&D investments to drive sustained innovation.

Cultivating Entrepreneurship and Translation

TONY HICKSON

Summary: This keynote and Q&A session delved into the entrepreneurial journey in the biotech sector, from research to market. It included insights on overcoming challenges and the importance of a supportive ecosystem.

Key Facts:

• Successful biotech entrepreneurs often emerge from environments rich in resources, mentorship, and funding opportunities.

• Translating research into commercial products involves navigating regulatory landscapes and securing investment.

• Sustainable business models and long-term planning are critical for enduring success.

Lessons Learned:

• A robust entrepreneurial ecosystem is vital for fostering innovation and supporting biotech startups.

• Effective translation from research to market requires a combination of scientific expertise and business acumen.

• Long-term sustainability should be a core focus, ensuring that business practices support ongoing innovation and growth.

Navigating Tax: Importance of Early Planning

CAROLE LE PAGE•STEVEN LEVINE

Summary: This session underscored the critical role of early tax planning for biotech companies, highlighting strategies to optimise financial outcomes and ensure compliance.

Key Facts:

• Early and strategic tax planning can help biotech companies mitigate risks and leverage tax incentives.

• Tax credits for R&D activities can significantly reduce financial burdens.

• Compliance with tax regulations is crucial to avoid penalties and ensure smooth operations.

Lessons Learned:

• Proactive tax planning is essential for optimising financial health and sustainability in biotech ventures.

• Utilising tax incentives and credits can provide substantial financial benefits and support R&D efforts.

• Understanding and adhering to tax regulations is critical for maintaining compliance and avoiding legal issues.

SPOTLIGHT ON: The Benefits of London as a Listing Venue for Your Company

TIM DAVIS

Summary

Tim Davis presented a comprehensive overview of the benefits and current landscape of London as a listing venue for companies. He highlighted the resilience and opportunities within the UK's financial markets despite global economic challenges, emphasising London's robust infrastructure for supporting growth companies.

Key Points:

1. Market Conditions and Trends:

   • The global economic backdrop, including geopolitical tensions and economic policies, continues to impact investor sentiment and stock market performance.

   • Despite these challenges, recent signs indicate a positive shift, with fund redemptions slowing and new inflows beginning.

   • Early look meetings for IPOs and existing companies seeking to raise funds are becoming more common, signalling renewed investor interest.

2. London’s Financial Health:

   • The UK maintains a substantial pool of capital in both public and private markets.

   • The perception of doom and gloom around companies leaving the UK market is often sensationalised; many companies move on to different funding types after their tenure in public markets.

   • London remains insulated from many global economic disruptions, maintaining a stable environment for businesses.

3. Regulatory and Structural Reforms:

   • The London Stock Exchange (LSE) is actively involved in regulatory reforms to make public markets more accessible and attractive.

   • Initiatives like the Mansion House Compact aim to unlock £50 billion from defined contribution pension funds for investment in tech and life sciences.

   • Efforts are underway to address disparities in executive pay and improve investment conditions for UK-based companies.

4. Advantages of Listing in London:

   • London offers a well-integrated ecosystem of growth company investors and advisers who understand businesses from seed stages onwards.

   • The UK boasts a world-leading tax-efficient grant environment, supporting companies from early stages through venture capital trusts.

   • AIM, the LSE's market for smaller growth companies, provides significant tax efficiencies and a supportive infrastructure for companies of various sizes.

5. Comparative Insights with the US:

   • While NASDAQ is often seen as a go-to for growth companies, London offers a more cohesive investor environment for early-stage companies.

   • UK companies listed on NASDAQ often face challenges due to size and liquidity issues compared to their US counterparts.

   • London provides a less litigious and more cost-effective environment for listings, with fewer class actions compared to the US.

6. Capital Market Dynamics:

   • London’s capital markets offer significant opportunities for companies to raise funds at various stages of growth.

   • The secondary market for share sales is well-structured, providing liquidity and opportunities for founders and management teams.

   • The LSE's regulatory framework is designed to be flexible and supportive, making it easier and cheaper for companies to list and remain on the market.

Inflation Reduction Act: Insights and Implications

DUNCAN MCHALE•JAMES FRY•EMMA TINSLEY•DEAN GRIFFITHS•PREMAL PAJWANI

Summary: This panel discussion explored the potential impact of the Inflation Reduction Act on the biotech industry, with a focus on drug pricing and market dynamics.

Key Facts:

• The Inflation Reduction Act aims to control healthcare costs, potentially affecting drug pricing strategies.

• There are concerns about the act’s impact on investment in R&D and overall innovation within the biotech sector.

• Regulatory changes necessitate strategic adaptations by biotech companies to remain competitive.

Lessons Learned:

• Controlling healthcare costs is beneficial for patient access but may pose challenges for biotech profitability.

• Companies must balance cost control measures with the need to invest in innovative research and development.

• Staying informed about regulatory changes and adapting strategies accordingly is essential for maintaining market position.

Leadership in Life Sciences SMEs

Summary: This panel discussion highlighted the unique challenges and opportunities faced by leaders of small to medium-sized enterprises (SMEs) in the life sciences sector.

Key Facts:

• Effective leadership in life sciences SMEs requires a blend of scientific knowledge, business strategy, and interpersonal skills.

• Securing funding and managing growth are primary challenges for SMEs.

• Maintaining core values and scientific integrity is crucial for long-term success.

Lessons Learned:

• Successfully securing funding involves presenting a compelling vision and demonstrating business acumen.

Regulatory Review: Updates and Challenges

CHRIS CARR•LISA PAGE•KIRSTY WYDENBACH•CAROLE PUGH

Summary: This session provided an overview of recent regulatory updates affecting biotech and medtech SMEs and discussed strategies for compliance and overcoming challenges.

Key Facts:

• The regulatory landscape for biotech and medtech is continually evolving, with frequent updates impacting compliance requirements.

• Developing robust compliance strategies is essential to avoid market entry delays and legal issues.

Lessons Learned:

• Implementing effective risk management practices can help mitigate regulatory challenges and ensure operational continuity.

Investment Deals: What Investors Really Want

MARINA BHAMAN•STEPHANIE LÉOUZON•GONZALO GARCIA•ALLAN MARCHINGTON•JAN-PHILLIP KRUSE•DAVID MOTT

Summary: This session focused on understanding the key factors that investors look for in biotech ventures, including value proposition, business strategy, and paths to profitability.

Lessons Learned:

• Investors seek a clear and compelling value proposition, demonstrating a well-defined product and market need.

• Strong business acumen and strategic planning are crucial for attracting investment.

• A clear path to profitability, with realistic financial projections and milestones, is essential for securing funding.

Disclaimers:
* My personal notes should be largely correct, though I'm only human!

One day I’ll get you to … Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

Permalink

]]>BioTrinity Unplugged: An Insider’s PerspectiveLola AnaidTue, 02 Jul 2024 22:10:19 +0000https://www.anaidbenitez.com/entrepreneurs-notebook/esmo-gynae246526e84a08859a53d0aeb713:65afdcdbd951e626b5430ec6:6681d47ae15ed3236f07b30b

The ESMO Gynaecological Cancers Congress, one of the most anticipated events in the oncology calendar, recently concluded in Florence, Italy. This event, known for its critical updates and breakthroughs in gynaecological cancer treatment, did not disappoint. Here are some of the key insights and discussions from the congress.

Did you know?

1. Successfully removing all visible tumours in ovarian cancer surgery can add 2.5 to 5 extra years to a patient’s life.

2. Surgical expertise matters! Getting surgery at specialised centres can significantly improve survival rates for ovarian cancer patients.

3. Healthcare Postcode Lottery is a thing… In the UK, where you live can drastically affect your treatment outcomes due to variations in surgical practices. So head to your GP and demand a referral to a specialised centre!

4. Rapid BRCA testing could contribute to timely treatment decisions and improving patient outcomes, but it currently takes way too long to get the results.

5. Half of BRCA-mutated ovarian cancer patients don’t benefit from PARP inhibitors due to various resistance mechanisms. Key lesson: look beyond BRCA.

6. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) therapy shows promise in treating ovarian cancer when combined with surgery.

7. Low-Grade Serous Carcinoma: This rare subtype of ovarian cancer requires different treatments due to its unique genetic markers.

8. The term “platinum-resistant” may soon be replaced with “platinum-ineligible” to better describe patient responses.

9. Antibody-Drug Conjugates (ADCs) are emerging as the magic bullet for targeted cancer treatment, reducing damage to healthy tissues while attacking cancer cells. But there are still so many challenges ahead…

10. Telesurgery, enhanced by AI and haptic feedback, could provide expert surgical care to patients anywhere in the world.

Why Doctors Struggle to Provide Optimal Care

Doctors want the best for their patients (that’s why they became doctors! ), but they’re often restricted by a chain of obstacles:

1. Regulatory Approvals: Local and international regulatory bodies set the standards, influenced by regional health policies and geography, impacting economic factors.

2. Economic Factors: Healthcare funding and budgets dictate treatment availability, shaping the design and scope of clinical trials.

3. Clinical Trial Outcomes: Economic constraints influence trial designs, which are driven by pharmaceutical companies and clinicians’ collaboration priorities.

4. Trial Design: Pharmaceutical priorities are driven by profitability, affecting the focus and resources allocated to treatments.

5. Pharmaceutical Priorities: Companies navigate different healthcare systems (public vs. private), impacting treatment implementation and accessibility.

6. Healthcare Systems: These systems limit the ability to address unmet medical needs, which doctors strive to improve.

Get the gist? 🌍🔬💊

For your information: The standard of care for advanced ovarian cancer typically includes surgery to remove as much of the tumour as possible, followed by chemotherapy with platinum-based drugs like cisplatin or carboplatin (types of chemotherapy drugs that contain platinum and are used to kill cancer cells), often combined with paclitaxel (a chemotherapy drug that stops cancer cell growth). Additionally, targeted therapies such as PARP inhibitors (drugs that block an enzyme used by cancer cells to repair DNA) or Bevacizumab (a drug that inhibits the growth of blood vessels that supply tumours) may be included, depending on the patient's genetic profile and response to treatment.

Surgical Excellence: The Key to Longer Survival

Philipp Carter’s presentation was a highlight, emphasizing that complete tumour resection (surgical removal) remains the gold standard in advanced ovarian cancer surgery. He shared a retrospective study (study that looks back at data from the past) that starkly illustrated disparities in treatment outcomes across different UK cancer centres, highlighting the importance of surgical expertise and specialised centres in improving patient outcomes. The study compared outcomes for patients with advanced epithelial ovarian cancer (EOC) treated at two neighbouring UK cancer centres (A and B) and found significant differences in practice and outcomes. Key differences included:

1. Surgical Rates: Patients at centre A were more likely to undergo surgery compared to those at centre B (87% vs. 59.8%).

2. Tumour Burden and Complexity: The median surgical complexity score was significantly higher at centre A compared to centre B (9 vs. 2).

3. Survival Rates: Center A had a higher rate of total macroscopic (anything that can be seen) tumour clearance (84.7% vs. 58.9%) and better overall survival rates compared to centre B.

4. Hospital Stays and Operation Times: Centre A had longer median operation times and hospital stays compared to centre B, reflecting more complex surgeries.

These variations highlight that treatment outcomes for similar conditions can differ significantly based on location, suggesting a disparity in healthcare quality and access within the UK's NHS. This underscores a critical message for patients: choosing a treatment centre with a proven track record in complete cytoreduction (complete removal of the tumour) can be a matter of life and death.

The Debate: Surgery vs. Chemotherapy

One of the more contentious topics was the role of upfront surgery versus Neo-adjuvant Chemotherapy (NACT). “Neoadjuvant" refers to treatments given as a first step to shrink a tumour before the main treatment, usually surgery, is performed.

The consensus? Upfront surgery still holds the upper hand, especially for BRCA wild-type cancers, as NACT can potentially induce resistance to platinum-based therapies. Antonio Gonzalez-Martin and Kathleen Moore stressed the importance of rapid BRCA testing, advocating for a turnaround time of just one week to make timely treatment decisions. The historical rationale was discussed, noting that the effect of surgery diminishes with the number of chemotherapy cycles in NACT. “If it’s true that we’re harming patients with BRCA (wt) with NACT, then we should 100% stop doing that. But they have to get the BRCA test back in a week,” said Kathleen. Additionally, cancers challenged with platinum NACT prior to primary debulking surgery (PDS) could acquire therapy resistance mechanisms, worsening prognosis.

Interval Debulking Surgery (IDS), as opposed to Primary Debulking Surgery (PDS), is not a standard solution for the problem of residual tumours in ovarian cancers and should not be used to hide “double left hand syndrome.” Clinical trial data is awaited to elucidate best practices.

Fragility Risk Factors

Clinicians must consider fragility risk factors that might indicate perioperative complications. "Perioperative" refers to the period surrounding a patient's surgical procedure. It encompasses three phases: preoperative, intraoperative, and postoperative.

Did you know that 23% of advanced ovarian cancer (AOC) patients fail primary standard therapy and relapse within a year? This highlights the urgent need to identify pre-op comorbidities and risk factors that might indicate surgical complications.

Addressing Platinum Resistance

Frederik Marmé’s session on platinum-resistant ovarian cancer (a type of ovarian cancer that does not respond to platinum-based chemotherapy) shed light on the complexities of treating this aggressive form of the disease. Platinum resistance mechanisms are diverse, including drug-efflux pumps (proteins that pump chemotherapy drugs out of cancer cells) and DNA repair protein up-regulation (increased production of proteins that repair damaged DNA in cancer cells). New strategies, such as targeting specific pathways and vulnerabilities, are being explored to overcome this resistance. Nicoletta Colombo suggested moving away from the term "platinum-resistant" to "platinum-ineligible" to better reflect the continuum of patient responses.

Challenges and Innovations in Molecular Diagnosis

Antonio Gonzalez-Martin presented on the four pillars of treatment: surgery, molecular diagnosis (identifying specific genetic and molecular characteristics of the tumour), chemotherapy, and PARP inhibitor maintenance (ongoing treatment to prevent cancer recurrence). Molecular diagnosis continues to be a cornerstone in the treatment of advanced ovarian cancer. Antonio pointed out a critical gap: the lack of reliable biomarkers (biological indicators) for selecting patients for Bevacizumab, a drug that inhibits angiogenesis (the formation of new blood vessels that supply the tumour). While KELIM (a score that predicts response to chemotherapy) can help select patients who may benefit most from Bevacizumab, confirmation in randomised clinical trials is eagerly awaited. The anticipation surrounding the results of the NIRVANA and AGO-OVAR 28 trials, which could provide much-needed clarity, was palpable.

Understanding PARP Inhibitor Resistance

A significant challenge in treating ovarian cancer is resistance to PARP inhibitors (drugs that block an enzyme cancer cells use to repair DNA). Antonio's discussion on the mechanisms of resistance was eye-opening. Did you know that 50% of BRCA-mutated (genetic mutation associated with higher cancer risk) patients do not benefit from PARP inhibitors? This resistance is often due to the restoration of homologous recombination (a DNA repair process), mitigation of replication stress (reducing problems during DNA replication), drug efflux transporters (proteins that pump drugs out of cells), and BRCA reversion mutations (mutations that reverse the original BRCA mutation). The search for better biomarkers (biological indicators), functional HRD tests (tests that assess homologous recombination deficiency), and the development of next-generation PARP inhibitors were highlighted as critical areas of ongoing research.

Selection Criteria for PARPi and Bevacizumab

Antonio discussed how to select HRD patients for PARPi+Bevacizumab versus PARPi alone. Platinum sensitivity is suggested as a surrogate marker for PARPi, with highly sensitive patients receiving PARPi alone and resistant patients receiving Bevacizumab alone. Criteria include favorable KELIM scores, near complete response by RECIST, and high CRS if NACT. However, there’s no perfect correlation between KELIM, RECIST, or CRS, so patients need to be evaluated case by case.

New Populations with Unmet Needs

New patient populations with unmet clinical needs were identified:

• HRD positive (homologous recombination deficiency) patients progressing during PARPi treatment: These patients do worse than those progressing after PARPi.

• HRD negative (homologous recombination proficiency) patients: What treatment to give them since they don't respond well to PARPi? Current focus is on the Antibody-Drug Conjugates (ADCs) space with seven trials in process and the potential of WEE1 inhibitors and CDK2 inhibitors.

Future of HRD Testing

Current HRD tests have limitations, including costs, availability, and a binary classification of a continuous variable. Issues like tissue quality, tumour selection, and ignoring tumour evolution (spatial and temporal heterogeneity) affect test reliability.

Good news: we're developing a comprehensive functional HRD assay to overcome current limitations.
Contact me for details.

Proffered Papers: Breakthroughs and Ongoing Trials

Several proffered papers presented at the congress showcased cutting-edge research and clinical trials. Notably, the MIRASOL trial demonstrated the efficacy of mirvetuximab soravtansine in platinum-resistant ovarian cancer, positioning it as the new standard of care for patients with high folate receptor-alpha expression. Additional significant trials include the DUO-O study, which showed a progression-free survival (PFS) benefit with durvalumab + chemotherapy + bevacizumab followed by durvalumab, bevacizumab, and olaparib maintenance in HRD-positive (homologous recombination deficiency) patients.

The Promise of Telesurgery

One of the most exciting prospects discussed was the future of telesurgery. Giovanni Scambia presented on the potential to democratise access to expert surgical care globally. By integrating artificial intelligence and machine learning, telesurgery could ensure that patients in remote locations receive the same quality of care as those in top-tier medical centres. Haptic feedback systems will allow surgeons to feel tissue textures even when operating from miles away, potentially revolutionising surgical precision and patient outcomes.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Jean-Marc Classe highlighted the potential of HIPEC in treating ovarian cancer. Despite the current lack of robust trial data, HIPEC could be a valuable option, particularly in first-line treatment at interval surgery and in first relapse treatment after six cycles of second-line chemotherapy. Standardizing HIPEC protocols will be crucial to its broader adoption and success.

Low-Grade Serous Carcinoma: A Unique Challenge

Low-grade serous carcinoma (LGSOC), a rare subtype of ovarian cancer, presents unique challenges. Anais Malpica emphasized that LGSOC has a low mitotic index and distinct genetic markers, necessitating different therapeutic approaches compared to high-grade serous ovarian cancer (HGSOC). Complete resection at primary debulking surgery remains the most important prognostic factor, once again underscoring the need for specialised surgical teams. Fabrice Lecuru pointed out that patients are younger at diagnosis of LGSOC compared to HGSOC and also stressed the importance of sending patients to expert centres to achieve complete resection.

Antibody-Drug Conjugates (ADCs): A Promising Frontier

Toon Van Gorp's discussion on ADCs highlighted their potential as a "magic bullet" in cancer treatment. ADCs aim to reduce off-target toxicities by delivering cytotoxic drugs directly to cancer cells. However, challenges remain, including patient selection, managing adverse events, and addressing resistance. Despite these hurdles, ADCs like mirvetuximab soravtansine are showing promise in clinical trials.

Future Directions in Clinical Trials

The congress also emphasised the need for better-designed clinical trials. Mixed responses during the Q&A sessions underscored the importance of considering HRD status and other biomarkers in trial designs. The consensus was clear: more functional markers and comprehensive testing are needed to tailor treatments effectively. Christina Fotopoulou remarked that clinical trials should account for tumour biology, not just stage and tumour burden.

Conclusion: A Bright Future Ahead

The ESMO Gynaecological Cancers Congress 2024 highlighted significant advancements in the treatment of ovarian cancer. From surgical innovations to emerging therapies and the potential of AI and radiomics, the future looks promising. As we continue to push the boundaries of science and medicine, the ultimate goal remains clear: improving patient outcomes and extending lives.

For more detailed information on the studies and data presented at the congress, visit the ESMO website.

Additional Resources

• Annals of Oncology: For detailed studies and clinical trial results, check the Annals of Oncology.

• Cancer Treatment Reviews: Explore more about the mechanisms of drug resistance in ovarian cancer on Cancer Treatment Reviews.

• Precision Oncology: Learn about the latest advancements in genomic testing and personalised treatment approaches on Precision Oncology.

Disclaimers:
* I’m a scientist, not a clinician.
** My personal notes should be largely correct, though I'm only human!

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

Permalink

]]>Surprising Insights on Ovarian Cancer Treatment (ESMO 2024)Lola AnaidSun, 30 Jun 2024 20:51:11 +0000https://www.anaidbenitez.com/entrepreneurs-notebook/economic-curve6526e84a08859a53d0aeb713:65afdcdbd951e626b5430ec6:65ff50a51849862768fe52aa

Have you ever been asked to perform a PESTLE analysis? Naturally, I had no idea what a PESTLE was… other than it went with a mortar and every Cuban kitchen had to have one at arm’s length.

Turns out a PESTLE analysis can be very useful for small (and big) companies.

A PESTEL analysis is an acronym for a tool used to identify the macro (external) forces facing an organisation (See more).

I won’t focus on the entire PESTLE… But here are some of the economic lessons I learned earlier this year through my Board Observer role at OBN, which could be of use to my fellow innovators and entrepreneurs:

For emerging entrepreneurs, especially in the life sciences sector, 2024 holds a variety of critical factors to consider for staying ahead in a rapidly evolving economic landscape. Here are some key takeaways and strategies for entrepreneurs to navigate the upcoming year effectively:

1. Stay Informed on Economic Indicators: With the anticipation of elections in both the US and UK, significant shifts in economic policies affecting the life sciences sector could occur. Entrepreneurs should monitor indicators such as GDP growth and healthcare expenditure to anticipate and adapt to changes that could impact investment and funding availability.

2. Monitor R&D Spending Trends: Research and Development (R&D) spending is a vital indicator of the sector's health. An increase in both public and private R&D expenditure suggests a favourable environment, while a decrease could signal potential challenges. Keeping an eye on these trends can help entrepreneurs align their innovation strategies accordingly.

3. Leverage Venture Capital Activity: The amount of venture capital investment is a strong indicator of the sector's growth potential. Despite global economic downturns, the UK life sciences sector has remained an attractive destination for venture capital, indicating sustained investor confidence. Entrepreneurs should consider this when exploring funding options.

4. Prepare for IPO Opportunities: The initial public offering (IPO) market has experienced a slowdown, making it essential for companies considering going public to be well-prepared. Entrepreneurs should focus on building a strong company narrative, realistic valuation, and exploring alternative funding sources.

5. Consider Global Opportunities: The UK's trade balance in pharmaceuticals and medical devices highlights the importance of international competitiveness. Entrepreneurs should not limit their market focus to the UK alone but explore opportunities in other regions as well.

6. Adapt to Inflation and Employment Trends: Inflation rates and employment trends within the life sciences sector can affect operational costs and talent acquisition. Entrepreneurs should develop strategies to mitigate these challenges, ensuring sustainable growth and innovation.

7. Utilise Government Support and Initiatives: Significant government investments and initiatives aimed at bolstering the life sciences sector, such as the £650 million growth package and support for early-career researchers, provide valuable opportunities for startups and established companies. Entrepreneurs should take advantage of these initiatives to accelerate their growth and innovation efforts.

GDP Growth

The overall growth of the economy can influence government spending and investment in life sciences. A strong economy might mean more funding, whereas a weaker economy might lead to the government cutting back on spending. 

United Kingdom GDP Growth Rate

“Healthcare expenditure represented 11.3% of gross domestic product (GDP) in 2022, lower than the share of 12.4% in 2021. This reduction was caused by nominal growth in healthcare expenditure being outpaced by growth in the overall economy in 2022.” (Ons.gov.uk)

“Planned total health spending will increase to £192bn in 2024/25 but inflation means that, on current plans, this would equate to a small increase of 0.6% in real terms compared with 2023/24 and a real-terms reduction in funding compared with 2022/23.” (Health.org.uk)

Research and Development Spending

Both public and private R&D expenditure are key indicators of the health of the life sciences sector. An increase can signal a favourable environment, while a decrease may suggest forthcoming challenges.

According to the latest Office for National Statistics (ONS) release, the total expenditure on R&D that was performed in the UK was £66.2 billion in 2021. The breakdown is as follows:

• The business sector accounted for £46.9 billion, which is 71% of the UK total.

• The higher education sector accounted for £14.9 billion, which is 23% of the UK total.

• The government sector, including UK Research & Innovation, performed R&D worth £3.4 billion, which is 5% of the UK total.

• The private non-profit sector performed the least amount of R&D at £1.0 billion, which is 1% of the UK total.

Venture Capital Activity

The amount of venture capital investment in the life sciences sector is a strong indicator of its health and potential for growth. A rise in venture capital indicates investor confidence, while a decline could signal a tightening of resources.

For the latest details on investments and support for the life sciences sector, the BioIndustry Association (BIA) offers reports and insights, while the British Business Bank provides information on its backing of innovation in life sciences.

“Despite the global economic downturn, UK life sciences companies secured £1.25 billion in venture financing, constituting 11% of the total venture capital investment in UK companies this year. This share has been maintained even amid the decline in investment from the remarkable highs of 2021, suggesting that the decline in investment is likely due to economic conditions and global events rather than industry-specific reasons. The sector therefore remains an attractive and reliable destination for venture capital investments.” (BIA)

The situation with the IPO market can be summed up like this:

In the past years, fewer companies decided to go public in the UK, and those that did raised less money than before. This slowdown was partly because of tricky economic conditions, like prices going up and the cost of borrowing money increasing, which made investors more cautious.

What does this mean for you as an entrepreneur with an eye on growth?

1. Be prepared: If you're thinking of taking your company public, it's more important than ever to be ready to move when the time is right. The IPO "windows" could open briefly – that means there might only be short periods when the conditions are favorable for an IPO.

2. Solid story: You'll need a strong story about what your company does, how it makes money, and its potential for growth. Investors will be picky, and they’ll want to see a track record of success and clear future profitability before they put their money in.

3. Valuation matters: Be realistic about how much your company is worth. Over the past couple of years, there's been a shift, with investors focusing more on the actual value and performance of companies rather than just potential.

4. Alternative options: Remember, going public isn't the only way to raise capital. Look into other funding options too, like venture capital or partnerships, which might be more suitable in the current economic climate.

5. Stay informed: The market can change rapidly, so keep an eye on financial news and trends. This way, you can plan better for the future and time your decisions wisely.

6. Potential for recovery: Although the IPO market has been quiet, there's hope that it could pick up. If economic conditions start to stabilize and investors become more confident, we might see more IPO activity.

7. Think global: As much as we’d hate to see you go, the UK isn't the only market. Depending on your business, you might find opportunities elsewhere.

As you grow your business, you may eventually reach a point where an IPO makes sense. By then, hopefully, the market will be more welcoming. Until that time comes, focus on building a strong, profitable business with a compelling narrative that will attract investors, wherever you decide to raise funds​​​​​​.

A few notable life sciences companies have successfully gone public in early 2024, signalling potential opportunities for others considering this route (see Xtalks).

Tim Davis, Regional Head of UK Primary Markets at the London Stock Exchange, spoke at BioTrinity 2024, organized by OBN, about the resilience and attractiveness of London as a listing venue amidst global uncertainties. He highlighted that despite significant global challenges such as the ongoing war in Ukraine, unpredictable actions from leaders like Putin and Trump, and volatility in the Middle East, the UK remains largely insulated on a day-to-day basis. Davis pointed out that these global issues create nervousness among investors, leading to cautious behaviour. However, he noted positive signs of recovery and momentum, indicating that the period of investor redemptions has slowed or stopped.

Inflation Rates

Inflation can affect the cost of research, development, and production in life sciences. High inflation may lead to increased operational costs and reduced purchasing power.

UK Inflation rate

Employment Rates in Life Sciences

Employment trends within the sector can indicate its current health and predict future growth or contraction.

UK Employment Rates

Government Budget Allocations

Changes in budget allocations to life science sectors, including education, research, and health services, are direct indicators of the government’s support.

Chancellor reveals life sciences growth package to fire up economy

A £650 million war-chest to fire up the UK’s life sciences sector and drive forward the government’s priority to grow the economy was unveiled by the Chancellor of the Exchequer Jeremy Hunt on 25 May 2023.

Science, Innovation and Technology backed in Chancellor’s 2023 Autumn Statement

£500 million investment in artificial intelligence (AI).
Five new Quantum Missions launched to promote technology.
£4.5 billion in funding for British manufacturing to increase investment in eight sectors across the UK.

Women-led high-growth enterprise taskforce
(Meeting minutes last updated Feb 2024)

The purpose of the taskforce is to increase the number of women-led high-growth businesses, with a particular focus on regions outside of London. The £250 million funding pot will come from a combination of pension funds and other private sector investors, as well as government monies.

Spring Budget 2024 life sciences announcements (March 2024)

The recent Spring Budget introduced several significant initiatives aimed at boosting the UK's life sciences sector:

1. Venture Capital-Pension Fund Consortium:

   • A pioneering venture capital-pension fund consortium has been launched to drive investment in life sciences.

2. Pensions Value for Money Reforms:

   • Reforms to the pensions Value for Money framework have been announced, with the goal of enhancing long-term investment outcomes.

3. R&D Tax Relief Advisory Panel:

   • To streamline the R&D tax relief process, an expert advisory panel will be established.

4. AstraZeneca Investment:

   • AstraZeneca has committed to a notable investment of £650 million, further strengthening the UK's life sciences industry.

5. Support for Life Sciences Manufacturing:

   • New government investments have been pledged to support life sciences manufacturing.

6. Focus on Talent Development:

   • There is an increased focus on nurturing talent, with additional funds allocated to support early-career researchers and apprenticeship programs.

These measures collectively aim to fortify the UK's position as a leading hub for life sciences innovation and business growth. For a detailed exploration of these announcements, please refer to the BIA website.

Science and Technology Framework (Last updated 9 February 2024)

Investment in R&D reaching £20bn per year by 2024/25.

For entrepreneurs and businesses in the life sciences sector, these developments suggest a favorable environment for growth and innovation, backed by government support and funding. It's an opportune time for startups and established companies alike to leverage these initiatives for their strategic advancement.

Trade Balance

The trade balance is a measure of the difference in value between a country's imports and exports over a certain period.

If a country exports more than it imports, it has a trade surplus.
If a country imports more than it exports, it has a trade deficit.

The trade balance is an essential indicator of a country's economic health and can affect exchange rates, levels of foreign reserves, and overall economic policies. The trade balance in pharmaceuticals and medical devices can provide insights into the international competitiveness of the domestic life sciences sector.

In 2023, the UK imported £25.4 billion worth of medicinal and pharmaceutical products, leading to a trade deficit of approximately £700 million. (ABPI)

Creating trade policy for a life sciences superpower by the Association of the British Pharmaceutical Industry (ABPI)

Disclaimers:
* I’m no economics expert…

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

OBN aims to create an enhanced environment to support the development and growth of OBN Member organisations within the innovative Life Sciences sector.

In preparation for the ~Board Observer interview, I learned several lessons, not just about OBN, but about the very fabric that constitutes the life sciences ecosystem. OBN's key drivers—networking, partnerships, and connections to investors, among others—resonate deeply with my own professional aspirations. Aligning with an organisation that advocates for innovative companies, promotes their growth, and provides industry advice and training was a natural fit for me.

To prep for my interview, I closely examined OBN's membership structure, which includes accessibility for various entities, from micro-companies to international pharmaceutical giants. This is pivotal for the sector and underscores the importance of inclusivity in fostering a thriving life sciences community.

As an emerging entrepreneur myself, I am intimately familiar with the hurdles that can hinder growth and innovation. Access to resources, both financial and educational, as well as meaningful connections, can make the difference between an idea that flourishes and one that fails. With my new role, I am committed to ensuring that these obstacles are mitigated, allowing brilliant minds to reach their full potential.

My vision as a Board Observer is to act as an ambassador for my fellow emerging entrepreneurs.

I will champion their voices within OBN, ensuring that their needs and insights contribute to shaping the strategic decisions of the organisation to better serve the needs of early-career translation scientists. From the insightful board meetings, which I plan to attend with a keen ear and a voice ready to articulate the collective aspirations of emerging entrepreneurs, to engaging with events like BioSeed and BioTrinity, where I will soak up and disseminate the valuable knowledge that these platforms offer.

I am determined to build bridges between OBN's initiatives and the emerging entrepreneurs who stand to benefit from them. This means not only conveying the benefits of membership, such as access to CROs, the Purchasing Consortium (which offer tangible cash savings for those companies with laboratories), or the diverse training opportunities, but also actively seeking feedback and ideas to enhance OBN's offerings.

In this rewarding role, I'm excited to gain insider knowledge on governance, draw wisdom from a spectrum of experts, and forge connections within the sector. While the required board-level analysis is intimidating, placing me squarely outside my comfort zone, I repeat to myself: "Nothing ventured, nothing gained."

To my fellow emerging entrepreneurs, consider me your advocate. I urge you to reach out and share your stories and challenges. Join me in this exciting venture as we strive for a vibrant, inclusive, and innovative life sciences ecosystem.

Did you know?

OBN offers a range of events that provide complimentary access to students and academic scientists within the life sciences community and the chance to engage with leading industry experts.

For those near Oxford, you won't want to miss the upcoming Science Socials, where ideas and insights flow freely. Details for a forthcoming Oxford Science Social here.

Looking ahead to May, the next BioTuesday at Oxford Tech Park promises to spotlight the latest R&D in cell and gene therapy. The live booking page is up here.

And there's more—BioTrinity is offering free Poster Presentation opportunities. It's an invaluable platform for showcasing your research to potential partners and investors. Find the full details here. Don't miss these chances to learn, network, and shine in the life sciences arena!

A Looming Challenge and a Call to Action

CRUK's campaign comes at a critical time. With global cancer cases predicted to surge by 50% by 2040, the urgency for breakthroughs in cancer research has never been more pronounced. In the UK alone, a 15% reduction in cancer mortality rates by 2040 could spare 110,000 lives over the next two decades. Michelle Mitchell OBE, CRUK's Chief Executive, encapsulates this sentiment by stating, "We stand on the brink of discoveries that will transform how we understand and treat cancer." However, these groundbreaking discoveries hinge on one crucial element: investment.

Bridging the Funding Gap

The campaign shines a light on a significant funding gap in cancer research. CRUK's report highlights a stark reality: a shortfall of over £1 billion needed for cancer research in the coming decade. With charities shouldering 62% of this financial burden, the call for philanthropic partnership becomes ever more pressing. The campaign has already garnered substantial support from philanthropic entities, a testament to the collective will to combat this disease.

The Crick's Role and the Emphasis on Translation and Innovation

At the Francis Crick Institute, where I am fortunate to contribute as a translation scholar, the emphasis on translation and innovation is palpable. Our work is at the forefront of transforming scientific discoveries into diagnostic tools and therapies that can directly benefit patients. The "More Research, Less Cancer" campaign underscores the importance of supporting scientists at every career stage, supporting an environment where innovation can thrive.

A United Front Against Cancer

The campaign's vision is one of unity and collaboration. It calls for a concerted effort among scientists, researchers, clinicians, and entrepreneurs across disciplines and continents. The video featuring notable figures such as journalist Victoria Derbyshire, Michelle Mitchell OBE, Sir Paul Nurse, and Professor Charles Swanton,  among others, serves as a powerful reminder of the collective expertise and dedication driving this campaign.

The Future of Cancer Research

As a translation scholar, I am particularly inspired by the focus on personalised approaches to cancer diagnostics and treatments. The development of platforms to assess the DNA repair capacity of tumour samples, as I am working on, is just one example of the innovative work being propelled by this campaign. Personalised medicine represents the future of oncology, promising more effective and targeted therapies for patients.

A Call to Innovators and Philanthropists

The "More Research, Less Cancer" campaign is a call to those with the means and vision to effect change. It's a call to philanthropists, innovators, and thinkers who can help bridge the funding gap and bring us closer to a world free from the fear of cancer. The campaign is not just about raising funds, it's about fostering an environment conducive to innovation, where scientific breakthroughs can flourish and lead to tangible improvements in patient care.

Last thoughts

In the words of Daniel Priestley from a recent Diary of a CEO podcast episode, "Environment dictates performance." The "More Research, Less Cancer" campaign is about creating an environment where scientific innovation can thrive, ultimately leading to a future where cancer is no longer a death sentence but a manageable condition. With the support of philanthropists and the wider community, we can embark on this ambitious path towards more research, less cancer, and a brighter future for all.

‘Letter to the World’

To mark the launch, Cancer Research UK has joined forces with a coalition of the world’s most renowned voices in the research community to pen a ‘Letter to the World’, calling on high-value donors and philanthropists to help tackle the disease.   

Read the letter here.

When: 15 Feb 2024

Where: University College London Faculty of Laws

Who: Translation experts, IP and patent experts, regulators, scientists, investors

Aim: The conference delved into the intersection of academia and commercialization, focusing on the implications of consumer protection laws for student treatment, especially regarding IP, revenue sharing, and equity policies. It examined the expectations from interns in technology development and IP ownership, the rights of academics to their IP, and how university policies on equity in spinout companies affect the commercialization of university IP. Drawing from the Oxford case and the Tracey/Williamson review, the event fostered discussions among scientists, university administrators, knowledge transfer experts, regulators, and investors, aiming to identify effective university approaches to these complex issues.

Host: UCL’s Institute of Brand and Innovation Law (IBIL)

Established in 2007, IBIL stands out as a premier UK intellectual property law research center, dedicated to impactful academic research with real-world application. Under the guidance of Professor Sir Robin Jacob, the institute excels in fostering dialogue between academia and the IP industry. Yesterday's conference is a testament to IBIL's commitment to bridging gaps and influencing IP practice and policy, reflecting its core mission of integrating scholarly excellence with practicality.

Key Lessons: extracted from my meeting notes

1. Intellectual Property (IP) and inventorship disputes have been a longstanding issue, with some obscurities in legislation dating back to 1977.

2. Clarity of IP assignment in employer/employee relationships is crucial for international protection.

3. PhD students are recognized as consumers and warrant clearer contractual agreements and protections. On the flip side, universities must be careful to protect the student’s freedom to operate.

4. The Oxford case highlighted trends such as the impact of consumer protection laws, changes in student status, and the rise in university commercialisation and independently sponsored students.

5. Academic curricula should foster academic citizenship, spreading the responsibility of fairness across the peer group rather than isolating it within individual student/teacher relationships.

6. Academic freedom is often more protected for supervisors than PhD students, raising concerns about the nature of project deliverables and student rights.

7. Commercially funded PhD projects should be managed carefully to protect freedom to operate and the academic research's nature.

8. Revenue sharing determinations should not be left to the student and group leader due to power imbalances; universities should play a role and possibly have independent reviews.

9. It's critical to have proper laboratory notebook practices to aid in inventorship determination.

10. Universities aim to maximise returns on IP, but must adapt to evolving guidelines and the increasing entrepreneurial expectations of their students.

11. The need for policy evolution is recognised, alongside the importance of reducing friction in licensing and equity negotiations.

12. There is a debate on the appropriateness of university shareholdings in spinouts and the influence of such stakes on the success of these ventures. Keep an eye out for Tomas Coates Ulrichsen's forthcoming paper on the subject.

13. The significance of distinguishing between inventors and founders was highlighted.

14. Universities must consider the full range of commercial risks and impact on reputation when engaging in litigation. However, they must be willing to defend their IP position, which will in turn increase the value of their IP.

15. A consistent global perspective is essential for universities when they adopt commercial stances on their IP.

16. Universities need to align with government guidelines to better support the ecosystem.

AI- rephrased and structured version of my raw notes:

WELCOME AND INTRODUCTIONS

• Professor Sir Robin Jacob provided a warm welcome and set the stage for the conference.

• Hon. Professor Mark Anderson reminded everyone of the pivotal themes stemming from the Oxford case.

PANEL 1 - Roles and Duties in Research; IP Ownership

• Discussion highlighted longstanding IP and inventorship disputes, with the 1977 Patents Act offering a solution that was not clear-cut.

• Emphasized the importance of clear IP assignment in international contexts beyond the employer/employee relationship defined by section 39.

PANEL 2 - Consumer Protection Laws and Student Fairness

• It was pointed out that students at all levels lack experience with contractual agreements; universities need to offer clearer contracts.

• The Oxford case was noted as a confluence of trends, including the increased power of consumer protection laws, changing student statuses, the growing commercialization of universities, and the rise of independently sponsored students.

PANEL 3 - Fair Treatment in Relation to IP and Spinout Issues

• The discussion proposed a shift in the academic curriculum toward creating academic citizens rather than focusing solely on consumer transactions.

• Fairness should be a collective responsibility, not isolated within individual relationships.

• Academic freedom is often more protected for supervisors than for PhD students.

• The nature of PhD projects, especially those that are commercially funded, should not be strictly defined to protect the student's freedom and the integrity of the research.

• Equity determination should involve the university due to power imbalances and possibly require independent review.

• Proper laboratory notebook practices are essential for determining inventorship.

PANEL 4 - Evolving University IP and Revenue Sharing Policies

• Universities seek to maximize IP returns and act as custodians of this IP.

• There was a call for policy evolution to align with government guidelines and accommodate students' entrepreneurial expectations.

• The discussion on whether there is scope for harmonization of guidelines suggested some alignment is present, but universities and government may view guidelines differently.

• Smaller universities face challenges with policy and resource implementation, and it was suggested that they might benefit from collective resources.

• What potential pitfalls should we be vigilant about in the future?

  • The first concern is whether there is an adequate delineation between the roles of inventors and founders. A positive outcome of the independent review has been the amplification of the founder's perspective.

  • Secondly, the ramifications of potential governmental shifts must be considered.

  • Thirdly, the challenge of demonstrating tangible impact and progress has emerged as a critical issue for the future.

  • Fourthly, there appears to be a reluctance to implement changes.

  • Lastly, there's a prevalent worry that entities beyond the university sphere may be outperforming academic institutions in certain respects.

PANEL 5 - University Shareholdings in Spinouts

• A range of university shareholding approaches exists across the UK, with more prominent universities showing flexibility in equity for founders.

• An upcoming study suggests a weak relationship between equity splits and success rates of ventures.

• The panel agreed that negotiation is key in licensing agreements, with a focus on how to resolve stakeholder differences.

• The appropriateness of public funding in the Oxford case for the development of commercial products was questioned but not elaborated on.

• How should equity be divided at the inception of a spinout? The challenge lies in balancing the company's early valuation against the developmental strides needed for market entry. Pinpointing a company's worth at the nascent stage, and forecasting its profitability before any actual returns, presents a complex puzzle.

• In negotiations, equity signifies not just the monetary value of shares but also the principle of fairness—both must be in harmony for all parties involved.

• As for areas of improvement within the UK, there's a call for:

  • Broader access to investment funds,

  • Enhanced funding for proof of concept stages,

  • A greater demonstration of impact to facilitate better funding opportunities.

• While equity divisions often take center stage in discussions about the UK's innovation landscape, they are but one facet of the broader economic forces at play. Nonetheless, investor confidence is paramount, and aligning with established benchmarks—such as the 5-10% non-dilutive share customary in the US—could streamline collaborations between universities and investors.

PANEL 6 - University Engagement in Commercial Litigation

• Universities should consider litigating more to protect their IP but need support to do so.

• Regular and systematic audits of licenses are crucial to prevent exploitation of inconsistencies.

• Universities must balance the desire to protect their IP with concerns about reputation, cost, and resources.

• Increased litigation could increase the value of university-held IP.

• What are the barriers for universities when it comes to pursuing legal action?

  • The resources available, often tied to the institution's size.

  • The dilemma of reputation management: Universities struggle to strike a balance between protecting their intellectual property without being perceived as aggressive litigants.

  • Financial constraints and budgetary considerations.

  • The potential financial risk if the litigation doesn't result in a favorable outcome.

  • The need for extensive time commitment from the university's senior leadership.

  • The magnitude and complexity of the legal case in question.

• Universities are encouraged to maintain a global perspective when commercializing their IP.

Observation:

• During lunch, a conversation with a commercialization executive at a UK university revealed a steadfast adherence to a near 50:50 IP policy. This was unexpected, considering the recent independent review advocating for reform, and it stood in contrast to the conference's emphasis on conforming to government guidelines for more equitable agreements.

• Nearing the end of the conference, IBIL graciously extended an offer to review the tech transfer policies of interested institutions, aligning with the conference's goal of fostering collaboration and improvement in this area. This gesture was commendable and presents a valuable opportunity for universities. Engaging with IBIL could provide institutions with expert insights and guidance, potentially enhancing their tech transfer strategies to be more effective, equitable, and in tune with the evolving landscape of academic commercialisation. It is hoped that universities recognize and seize this chance to refine their policies, ultimately benefiting their research communities and the broader ecosystem of innovation.

Useful Links Provided:

Mark Anderson and his team have written some published template agreements and guides for use by universities. They include:

1. In the UK, the PraxisAuril Practical Guides to Commercialisation (which include template agreements). Originally written 20 years ago, some of them were updated a few years ago. See  https://www.praxisauril.org.uk/resource/practical-guides

2. A more comprehensive and up-to-date set of guides and template agreements that were commissioned by an Irish government agency, Knowledge Transfer Ireland. Designed for use by Irish universities and to be suitable for use under Irish law, they can be found at: https://www.knowledgetransferireland.com/Model-Agreements/

Disclaimers:
* My personal meeting notes should be largely correct, though I'm only human!

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

1. IP Strategy Alignment: Ensure your intellectual property (IP) strategy is in line with your institution's goals for your technology. Broad and deep coverage is only beneficial if it aligns with the commercialization interests of all parties involved.

2. Building a Founding Team: Venture Capitalists (VCs) will scrutinize your ability to assemble a motivated and capable team that can effectively deliver your technology.

3. Forming Partnerships: Secure design partners early on and offer them early access to the technology. This is crucial for rapid advancement.

4. Securing Funding: Consider applying for an R&D Catalyst grant as a precursor to more significant investment. Incorporate as a Contract Research Organization (CRO) to potentially qualify for Innovate UK funds and foster commercial partnerships.

5. Scalable Business Models: Investors look for scalability due to limited funds in the diagnostics system, allowing targeting of various markets. For a pharma-focused model, consider revitalizing old IP for drug development.

6. Understanding Stakeholders: Recognize the needs of all stakeholders, including clinicians who seek simplicity, the NHS's cost-cutting goals, and the necessity to facilitate technology adoption.

7. Diagnostics Approach: Distinguish between companion and complementary diagnostics. Companion diagnostics are essential for the safe and effective use of therapeutics, while complementary diagnostics may improve the benefit/risk ratio without restricting drug access. Getting your product into patient stratification for Stage III trials is hard. Tests must be robust and extremely well validated.

8. Outsourcing Strategy: When considering outsourcing, identify which diagnostic centers could become your partners.

9. Financial Risk Management: Be aware of the financial risks and ensure you have enough funding to reach the next milestone in your development pathway.

Key Lessons from Investor 004: extracted from meeting notes

1. Deal Structure: Aim for full ownership of IP or consider a low royalty license. An institute equity split of 10-20% is reasonable, with the potential for founders to end up with 25-30% after negotiations over rounds of funding.

2. Equity and Options: Remember that the initial 10% in pool options can be a lever for renegotiating 2% back to the founder in subsequent funding rounds.

3. Leadership Composition: Having a postdoc as CEO is viable, provided they are supported by a strong board of directors.

4. Market and Scalability: Understand not just the market but the addressable market, considering factors like scalability, for instance, the accessibility of unfixed tissue in smaller hospitals.

5. Pharma vs Clinical Diagnostic Solutions: Weigh the feasibility of pharma solutions against clinical diagnostic solutions, noting that VCs tend to shy away from diagnostics products until they’re nearly market ready. Pharma solutions may be more feasible but clinical diagnostics might present a larger market.

6. Service Model Viability: Service models may not seem scalable and thus less attractive to investors. Market size and exit strategy are paramount for investors.

7. Starting as a Service Model: If considering starting as a service model, evaluate the necessity of VC funding versus growing organically through grants and small contracts.

8. Protecting IP: Build strong, protectable IP and ensure freedom to operate. F2O searches are expensive and usually conducted by investors during due diligence, but staying informed about the competitive landscape is crucial.

9. Networking and Contacts: Connect with entities such as Illumina Ventures and Deep Science Ventures, which could be valuable for support and insights. Take advantage of your local opportunities like the events planned by the Crick Science Entrepreneur Network.

ChatGPT’s witty reflection on my raw meeting notes:

Embarking on a dual-duel with the guardians of venture wisdom, I juggled the hats of a student, strategist, and stealthy founder. In the morning, with Expert 003 (names cloaked in mystery to protect the wise), it was like playing chess with IP—every move calibrated, every strategy echoing with the hushed tones of commercial conquest. We talked founding teams, the kind of teams that would make the Avengers pause for thought, and partnerships that offer early tech peeks like golden tickets in a Willy Wonka bar.

As the sun arched, the afternoon with Expert 004 felt like swapping my chessboard for a high-stakes poker game. Here we delved into the pot, pondering the chips of full IP ownership against the ante of equity splits. The talk turned to markets, scalability, and the alchemical transformation of a postdoc into a CEO—proof that sometimes the lab coat might just hide a business mogul.

By the time twilight beckoned, my mind buzzed with the thrill of service models versus clinical diagnostics, and the realization that in this high-octane biotech casino, the house—aka the investors—always eyes the exit. Oh, and let’s not forget the cheeky reveal of my role in the Crick Science Entrepreneur Network, a twist in the plot for my unsuspecting investor friend who so candidly steered me toward them.

As I bid adieu to both maestros, my notebook was richer, my entrepreneurial spirit fiercer, and my network just a hint more illustrious. All in a day's work for a biotech entrepreneur sailing the stormy yet exhilarating seas of innovation and investment."

Disclaimers:
* My personal notes should be largely correct, though I'm only human!
** Beware, ChatGPT fabricates quotes… clearly not human.

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

The MHRA have published a roadmap which outlines the intended timelines for delivering the future regulatory framework for medical devices.

The most relevant takeaways from the new UK regulations for innovative medical devices include:

• Alignment with EU Regulations: The upcoming UK regulations aim to align more closely with the European Device Regulations, especially concerning essential requirements for medical devices, including cybersecurity for software as a medical device. This alignment could facilitate smoother market access for your IVD in both the UK and EU markets.

• Regulatory Compliance and Quality Management: There will be a requirement for a Person Qualified in Regulatory Compliance within your organization. Also, the regulations will strengthen the requirements for quality management systems and technical documentation, which means your development process must adhere to these enhanced standards.

• Unique Device Identifier (UDI): Your IVD will need to have a UDI, which is part of the effort to improve traceability and safety of medical devices.

• Clinical Investigations and Post-Market Surveillance: New regulations will introduce stricter requirements for clinical investigations and post-market surveillance, ensuring that your IVD is continuously monitored for safety and effectiveness even after it reaches the market.

• Classification and Conformity Assessments: There may be changes in the classification of your IVD, aligning with international standards. Understanding the classification your device falls under will be crucial for meeting the specific regulatory requirements. Also, be prepared for the clarified conformity assessment procedures and the role of approved bodies in this process.

• International Framework and Market Access: The regulations aim to introduce a framework for international recognition, which could potentially make it easier for your IVD to gain access to markets outside the UK if it's already approved by comparable regulators or holds Medical Device Single Audit Program (MDSAP) certificates.

• Regulatory Strategy and Expert Support: Given the complexity of medical device regulations, it's recommended to plan your regulatory strategy early and consider seeking expert advice to navigate these requirements efficiently and ensure compliance.

• Timeline: Be aware of the timeline for these regulatory changes. Priority measures for patient safety, including post-market surveillance enhancements, are set to be implemented first, with the core elements of the new regulatory framework expected by 2025. This timeline will be crucial for your planning and development process.

This is meant to be a game-changer for startups and established companies alike, ensuring patient safety while fostering innovation. Planning our regulatory strategy early is more crucial than ever! 🌍💡

From my neophyte perspective, these changes seem to pave a promising path for innovation and market access, but I'm curious about your thoughts. How do you see these developments impacting the broader life sciences ecosystem?

Check out the full roadmap here: Implementation of medical devices future regime - GOV.UK

1. Commercial Strategy: To develop an effective commercial strategy, understand the pharmaceutical landscape, including how diagnostics are chosen as companion tests for targeted therapies.

2. Test Selection: Investigate the factors influencing the adoption of specific diagnostics by pharmaceutical companies, such as initial drug response in the clinic and the necessity of a companion diagnostic (Cdx). Consider whether a companion diagnostic is needed at all. What’s the benefit-risk profile?

3. Scalability and Adaptability: Ascertain the scalability of the diagnostic test for broad clinical application, and strategize to stay ahead in the clinical pathway integration. Complicated lab-based tests may not be scalable enough for clinical adoption or to derive profit margins for investors.

4. Clinical Development and Incentives: Recognize the influence of pharmaceutical companies' desires to expand labels and the contrasting governmental or insurer's restrictions, shaping the development pathway based on current and upcoming drug approvals and their benefit-risk profiles.

5. Diagnostic Testing Landscape: Examine the current performance of drugs in clinical trials, and consider the implications of new drugs on the pathway to market.

6. Pharmaceutical Technology Adoption: Explore the history of drug development and adoption, including the role of early-stage development, licensing, and the selection process between different lab tests for assessing drug efficiency.

7. Clinical Trial Design and Endpoints: Address the challenge of defining clinical benefits and business cases for functional tests, the ambiguity of proficient vs. deficient determination in the clinic, and the need for better treatment response metrics than RECIST.

8. Pathology Lab Insights: Spend time in a community pathology lab to understand feasible practices and commercialization potential, considering the limitations of the current system.

9. Live Cell Assay Challenges: Tackle the issues of requiring live cells for the assay and consider the logistics of sample handling in a clinical setting.

10. Target Discovery and Drug Combinations: Contemplate avenues for target discovery validation or designing rational combinations for new treatment strategies in collaboration with pharma, focusing on upcoming drugs.

11. Functional Assays vs. Genetic Screens: Evaluate how a functional assay could offer advantages over genetic screens in drug combination development and patient selection.

ChatGPT’s witty reflection on my raw meeting notes:

Navigating the sea of diagnostic development is a bit like being a pirate on the lookout for uncharted territories—exciting, unpredictable, and fraught with the occasional 'Argh!' moment. In my latest confab with Industry Expert 002 (name disguised to protect the not-so-innocent), I embarked on a quest to unearth the treasure map for commercial strategy in the wild waters of targeted therapy diagnostics.

IE002, with the wisdom of an old sea captain, steered the ship through the foggy waters of companion diagnostics, where the siren call of DNA repair inhibitors echoes through the pharmaceutical ocean. We pondered the enigma of how a test could be a trusty first mate on this voyage, adaptable enough for the high seas of clinical use and scalable like a pirate's ambition.

Our parley delved into the murky depths of the UK's clinical trial protocols, with HRD testing as our North Star, and how bizarre it would be to set sail years later with a new test—like plotting a course to the edge of the map where dragons be. We even raised a spyglass to the horizon, looking at the performance of the latest DDR drugs bobbing in the trial waters.

As IE002 spun tales of pharmaceutical buccaneers grappling over PARP inhibitors—a treasure nearly lost to the depths until positive trial data floated it back to the surface—I couldn't help but marvel at the strategic capers and close calls.

The chat ventured into the dark waters of VUS rates and diagnostic skirmishes. We charted the uncertain territories of functional tests, where the wind whispers of gene loss and methylation mysteries, and where the right assay could be the compass that guides us to therapeutic X marks the spot.

Yet, as we docked at the end of our meeting, I was left with a chest full of insights and a map riddled with new paths to explore. From the necessity of live cells in assays—akin to keeping a parrot squawking on your shoulder—to the looming specter of generics making the current bounty less shiny, the journey ahead is as thrilling as it is daunting.

So here I stand, a diagnostic buccaneer, charting a course through the choppy waves of innovation, partnership, and commercial viability, with IE002's parting shot echoing in my ears: spend time in a pathology lab, for that's where you'll find whether your diagnostic treasure can truly be unearthed.

Disclaimers:
* My personal notes should be largely correct, though I'm only human!
** Beware, ChatGPT fabricates quotes… clearly not human.

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

1. Decision-Making Inquiry: Engage with pharmaceutical companies or oncologists to understand who determines the choice of HRD tests (or test of choice) for patient stratification in clinical trials.

2. Regulatory Pathway Clarity: Determine the most efficient strategy for market access, considering the nuances between in-house testing, pathology lab test kits, and the implications of possible regulatory exemptions for preliminary studies performed in health institutions.

3. Clinical Trial Preparation: Ascertain the regulatory prerequisites for initiating clinical trials, focusing on the regulatory certifications, which at the onset may only need to cover the analytical performance of the IVD, not its clinical performance.

4. Transitioning from Prototype to Market: A robust system during prototyping is crucial to prevent failures during technical validation. Streamlining variables reduces costs and expedites the process.

5. Validation Strategy: Perform technical validation before clinical validation, ensuring thorough documentation. Differentiate the validation requirements for companion diagnostics, especially in oncology.

6. Commercialization Readiness: If creating a custom device as part of a bigger kit, consider CE marking it separately for easier technical validation and potential standalone commercialization.

7. Technical Validation Considerations: Aim to perform validation tests in an ISO 13485 accredited laboratory, ensure distinct positive/negative readouts, confirm primer specificity, and assess robustness across various conditions.

8. Manufacturing and Statistical Analysis: Test multiple batches and conduct release tests, involving a statistician to ensure sufficient sample power for confidence in the results.

9. Stability and Transport Testing: Validate the conditions under which samples can be transported without compromising the assay's effectiveness.

10. Software Regulation: Ensure the software component of the assay, including code practices, complies with regulatory standards.

11. Seeking Expertise: Leverage consultations with diagnostic labs and industry-specific consultants, like Almac, to refine the venture strategy and prepare for technical validation.

12. Grant Funding Strategy: Consider applying for Innovate UK grants during the final stages of prototyping and validation, budgeting for consultancy and validation study costs.

ChatGPT’s witty reflection on my raw meeting notes:

Navigating the labyrinthine world of diagnostics, I found myself at the crossroads of innovation and regulation—a place where every decision feels like choosing between the red and blue wire in a bomb defusal scene. In the realm of clinical trials, it turns out the pharmaceutical world's 'who's who' for selecting HRD tests is more tightly guarded than the recipe for grandma's secret sauce.

Industry Expert 001 (name anonymized for that secret-agent vibe) gave us the regulatory roadmap that had more twists and turns than a daytime soap opera. The key to faster market access? It's like choosing between an in-house band or a pathology lab's greatest hits kit—each with its own set of fanatical fans and regulatory groupies.

The regulatory discovery felt like speed dating with compliance codes—flirting with the UKCA, giving a wink to the CE, and batting eyelashes at the CE UKNI, all while only needing to showcase our analytical charm, not our full clinical performance—yet.

Transitioning from prototype to market is like teaching a toddler to run a marathon—start with a robust stroll and minimize those temper tantrums (aka technical variables). And when it comes to manufacturing, think of it as a bake-off where every batch is scrutinized by a panel of Gordon Ramsays—it's gotta be perfect.

Seeking expertise? We're on a first-name basis with diagnostic labs and contemplating a coffee date with Almac. But first, let's get a CDA—because no one wants their secret blend of herbs and spices tweeted out.

And as for grants, well, it's like playing the lottery, but instead of a lucky dip, it's all about aligning those ducks in a row, from technical validation all the way to the clinical stage. It's a game of strategic investment, with a little bit of who you know and a dash of bureaucratic charm.

In short, it's a dance between the cutting-edge of technology and the red tape of regulation, where one misstep could mean stepping on the toes of compliance—or worse, tripping into a pit of funding faux pas. But with a bit of luck and a lot of paperwork, we might just waltz our way through to innovation stardom.

Disclaimers:
* My personal notes should be largely correct, though I'm only human!
** Beware, ChatGPT fabricates quotes.. clearly not human.

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

Permalink

]]>Diagnostics Lessons from Industry Expert 001Lola AnaidTue, 23 Jan 2024 21:27:32 +0000https://www.anaidbenitez.com/entrepreneurs-notebook/symposium-scribbles6526e84a08859a53d0aeb713:65afdcdbd951e626b5430ec6:65afdd460a7ab424986de7e6What: Diagnostics Development Symposium

When: 19 Jan 2024

Where: The Francis Crick Institute in London

Who: Translation experts, diagnostics experts, industry leaders, Crick innovators

Aim: The Crick’s diagnostics symposium was kindly organized by Dr. Ranmali Nawaratne with the aim to bring together Crick innovators with industry experts to decode the development of diagnostics.

Key Lessons: extracted from meeting notes

1. Innovation Beyond Tech: Success may lie in improving existing systems and designs, not just in developing new technology.

2. Supply Chain Mastery: Know where your reagents come from, ensure you have a steady supply, and check for legal freedom to operate.

3. User Adoption: Understand the context in which the user operates. Your tech must be not only functional but also desirable and easy to integrate into existing workflows.

4. Focus for Platform Tech: If you’re developing a platform technology, pinpoint and prioritise key applications before seeking funding.

5. Sustainability Matters: Businesses may soon have to comply with sustainability mandates, which will influence investor decisions.

6. Clinical Translation is Tough: A high failure rate for biomarkers reaching clinical use emphasizes the need for broad evidence collection, beyond just clinical data.

7. Partnerships with Experts: Entities like LifeArc and NIHR London In Vitro Diagnostics Co-operative can provide essential lab services and clinical development expertise to move from publishing to clinical validation.

8. Structured Funding: UKRI-MRC-DPFS grants are laid out like a translation grant with clear criteria and timelines but are aimed for established projects rather than new lab setups.

9. Data-Driven Partnerships: Collaborating on technology with the top dogs in industry requires extensive data to navigate development and validation challenges successfully.

ChatGPT’s witty version of my raw notes:

In the bustling heart of London's biotech scene, the recent Diagnostics Symposium at the Crick Institute sent a clear message to aspiring entrepreneurs: innovation in diagnostics is not just about new tech, but smarter systems. John Pritchard, a maestro in the field, punctuated the event with insights that echoed in the halls like a clarion call for ingenuity. Forget the Silicon Valley rhetoric for a moment; success may well lie in the mastery of supply chains, from the reagents you source to the mundane yet crucial batch-to-batch variability.

For those with a product in the pipeline, Pritchard threw down the gauntlet, challenging attendees to ponder deeply: can you source enough reagents? Is your operation legally clear? Will users champion your product, or will it be another unwelcome step in their routine? And for those daydreaming about platform technologies, focus is your true north—identify your killer applications to woo the funding gods.

The London In Vitro Diagnostic Co-Operative, backed by the hefty acronyms of NIHR and ICL, delivered a sobering statistic: a staggering 97% of cancer biomarkers are relegated to the lab bench, failing to make the clinical cut. The lesson? Evidence is multifaceted. Aspiring moguls must venture beyond clinical trials, embracing everything from stakeholder management to economic analysis.

Meanwhile, LifeArc Diagnostics offered a beacon of hope with its ISO13485 certified lab services. After the fanfare of publishing, they're the ones rolling up their sleeves to replicate, refine, and validate—essentially, the due diligence investors salivate over, but with a collaborative twist courtesy of the Crick.

On the funding front, the UKRI-MRC-DPFS grant shined a spotlight on its structured approach, resembling a translation grant with its clear go/no-go criteria and well-defined timelines. However, new PIs be warned: this isn't your lab's setup fund—it's all about the project.

Finally, Iain D Miller of Presymptom Health capped the event, underscoring that technology partnering isn't for the faint-hearted. It demands data, heaps of it, to navigate the maze of lessons and hurdles.

To add to this treasure trove of wisdom, Tom Leonard from Kilburn & Strode chimed in with the kind of legal acumen that turns inventive sparks into fireproof assets. “Guard your innovations like a dragon hoards gold,” he quipped, reminding us that premature disclosure is the Achilles' heel of patent protection. Leonard’s mantra for success: consider your timeline meticulously, secure funding well before the 30-month mark, and strategize international filings with a global vision in mind. After all, the path from 'eureka' to 'economy' is paved with patented secrets.

Amidst the symposium's wealth of knowledge, we were tantalized by whispers of groundbreaking innovations brewing at the Crick (including a rather clever one of mine) and Owkin Diagnostics. But in the spirit of suspense and a bit of entrepreneurial mystique, those details are zipped up tighter than a hipster's skinny jeans—strictly confidential, of course!

So there you have it, straight from the frontline of diagnostic innovation and, cheekily enough, drafted with a helping hand from yours truly, ChatGPT, based on personal notes from an attendee with an entrepreneurial gleam in their eye. Who says AI can't be at the cutting edge of scientific symposiums?

Disclaimers:
* My personal notes should be largely correct, though I'm only human!
** Beware, ChatGPT fabricates quotes.. clearly not human.

Join the dialogue—reflect, share your tales from the trenches, and by all means correct me if you spot any erroneous information.

Most of my learnings are scribbled away in entrepreneurship notebooks in my lab. With a bit of luck and occasional bursts of motivation, they might have migrated to my computer, only to resurface during the next frantic grant writing session, the nth market analysis, or while prepping for that critical meeting with a very smart person in about an hour.

So, with a stroke of further luck, I might manage to squeeze one more task into my moonshot to-do list and share my learnings here. Don’t expect anything fancy or structured, and certainly not 100% accuracy - these are, after all, my personal notes. If I’m feeling adventurous and have 3 more minutes to spare, I’ll dump my raw notes into ChatGPT and ask it to extract the key lessons or create a witty story line for your amusement.

Tucked within my notes is the information that has led me to my current station as a Translation Scholar at The Crick. No promises for tomorrow, though, especially given the dangerous atmosphere.

Permalink

]]>Adventures in the Translationsphere